Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Indianapolis, Indiana 46202


The primary purpose of this study is to determine the efficacy and safety of daclizumab in preventing the progression of diabetes in children who have just been diagnosed with type I diabetes. Additional purposes of the study are to investigate the amount of drug in the children, how quickly it is eliminated from the blood, and analyze the effect of the drug on the immune reaction to diabetes.


Inclusion Criteria: - Newly diagnosed type 1 diabetes without previous insulin or oral hypoglycemic therapy. - ages 2 to 40 years at diagnosis - enroll within 3 months of diagnosis - test positive for at least one of the biochemical autoantibodies (ICA-512, GAD 65 or IAA) prior to enrolling Exclusion Criteria: - Previous treatment with an anti-IL-2 directed monoclonal antibody or any other investigational agent that would interfere with the ability to evaluate the safety and efficacy of daclizumab. - Other immunosuppressive drugs including, but not limited to, corticosteroids, cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, or azathioprine. - Active significant infection - Limited life expectancy because of disease other than diabetes - Pregnancy



Primary Contact:

Principal Investigator
Mark D Pescovitz, M.D.
Indiana University - Riley Hospital for Children

Backup Contact:


Location Contact:

Indianapolis, Indiana 46202
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.